

Special-Case Products: Imaging Agents and Oncology Drugs

1 INTRODUCTION

Special cases in the assessment of nonclinical safety arise from a variety of situations or for a number of reasons. We have already explored the major cases that arise as a result of different routes of administration—inhalation and topical routes with their variations. These are the most common variations from the general cases of oral and parenteral administration.

Likewise, the major cases associated with different physical forms (small molecules, being the general case, the major variation being biotechnology sourced materials) have been discussed.

In this chapter, two special cases which arise from the nature of the therapeutic use are considered: imaging agents (in vivo diagnostic agents) and oncology drugs.

2 IMAGING AGENTS

Medical imaging agents used for diagnosis or monitoring serve a variety of different modes of activity such as radiography, computed tomography (CT), ultrasonography, magnetic resonance imaging (MRI), and radionuclide